Ponfibrate
Code | Size | Price |
---|
TAR-T34111-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T34111-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T34111-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Ponfibrate is a hypobetalipoproteinemic and Lipid decreasing agent.
CAS:
53341-49-4
Formula:
C18H18Cl2O4
Molecular Weight:
369.24
Purity:
0.98
SMILES:
CCOC(=O)C1=CC=CC2[O](Cl)C[O](C)c3cc(Cl)ccc3C=C12
References
Nichols GA, Koro CE, Chan W, Bowlin SJ, Sprecher DL. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. Clin Ther. 2006 Feb;28(2):243-50. PubMed PMID: 16678645.
Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990 Aug;40(2):260-90. Review. PubMed PMID: 2226216.
Yang CC, Jick SS, Testa MA. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br J Clin Pharmacol. 2003 Jul;56(1):84-91. PubMed PMID: 12848779; PubMed Central PMCID: PMC1884321.